Wichmann Gunnar
ENT-Research Laboratory, Clinic of Otolaryngology, Head and Neck Surgery and Department of Head Medicine and Oral Health, University of Leipzig, Liebigstr. 21, 04103, Leipzig, Germany.
Recent Results Cancer Res. 2017;206:113-122. doi: 10.1007/978-3-319-43580-0_8.
The human papillomavirus (HPV) comprises a heterogeneous group of double-strand DNA viruses with variable potential to infect human epithelial cells and trigger neoplastic transformation. Its 8 kb genome encodes proteins required for virus replication and self-organized formation of infectious particles but also for early proteins E6 and E7 able to trigger neoplastic transformation. E6 and E7 of high-risk (HR) HPV subtypes can bind to p53 or release E2F and abrogate replication control. Due to variable amino acid sequence (AAS) in the binding sites of E6 and E7 particular HR-HPV variants within subtypes are essentially heterogeneous in efficacy triggering neoplastic transformation and cancer development. This could explain differences in the clinical course of HPV-driven head and neck cancer.
人乳头瘤病毒(HPV)是一组双链DNA病毒,具有异质性,感染人类上皮细胞并引发肿瘤转化的潜力各不相同。其8kb的基因组编码病毒复制和传染性颗粒自组装形成所需的蛋白质,也编码能够引发肿瘤转化的早期蛋白E6和E7。高危(HR)HPV亚型的E6和E7可与p53结合或释放E2F并消除复制控制。由于E6和E7结合位点的氨基酸序列(AAS)不同,亚型内特定的HR-HPV变体在引发肿瘤转化和癌症发展的效力上基本存在异质性。这可以解释HPV驱动的头颈癌临床病程的差异。